Taivex is dedicated to the development of novel cancer therapeutics and possesses multiple First-in-Class/Best-in-Class anticancer targeted drugs. Taivex will attend the Bio Asia-Taiwan 2024, BIO One-on-One PartneringTM to seek for potential collaboration partner for licensing out or co-development opportunities.
T-1101 is a First-in-Class oral capsule formulation. The enrollment of study subject of T-1101 Phase I clinical trial has been completed with encouraging safety and preliminary efficacy outcomes. Phase II IND application is in preparation. The target indication is neuroendocrine tumor (NET).
T-1201 and T-1501 are anti-cancer drug of novel small molecule drug conjugates, and are administered via intravenous infusion. T-1201 has shown promising safety and preliminary efficacy outcomes in the Phase I clinical trial, of which subject enrollment is coming to an end, and Phase II IND preparation is to be initiated in parallel. The target indications are melanoma and cholangiocarcinoma. T-1501 is in pre-clinical development, expected to enter Phase I clinical trial in 2025.
T-1301 is a multi-target tyrosine kinase inhibitor for oral use. The Phase I clinical trial is ongoing. The proposed indications for T-1301 are drug-resistant gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML), and may be reassessed based on the latest clinical data.
